The EXPAND trial is studying if adding radiation therapy to all sites of disease helps patients with pancreatic cancer that has spread to a few, limited areas (oligometastatic pancreatic ductal adenocarcinoma). This study compares patients who receive radiation therapy plus their usual systemic therapy (like chemotherapy) to those who receive only systemic therapy. Researchers want to see if radiation therapy can help patients live longer without their cancer getting worse (progression-free survival) and improve overall survival. They will also look at the safety of radiation therapy and how it affects quality of life. You may be able to join if you are 18 or older and have confirmed pancreatic ductal adenocarcinoma.

Study design

This is a randomized Phase III interventional study, meaning participants will be assigned by chance to one of two treatment groups. The study plans to enroll 80 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.